Nudge for Ovarian Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What is the purpose of this trial?
Ovarian cancer lacks an effective screening test, and prompt treatment at diagnosis is the only way to improve outcomes. Referral to gynecologic oncology at diagnosis of adnexal mass is recommend by guidelines from every major medical organization. Yet, 1 in 4 patients with ovarian cancer nationwide and at Penn Medicine never see a gynecologic oncologist. Even when referred to gynecologic oncology, patients from historically-marginalized groups have twice as long duration from diagnosis to seeing gynecologic oncology. In this project, the investigators will pilot a clinician nudge to gynecologic oncology referral and compare the impact to historical controls.
Eligibility Criteria
This trial is for individuals diagnosed with ovarian cancer, peritoneal neoplasm, or fallopian tube cancer. It aims to improve the referral rate to gynecologic oncology specialists at diagnosis. The study focuses on patients who have not yet seen a gynecologic oncologist.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Clinician nudge to gynecologic oncology referral for patients diagnosed with a complex adnexal mass
Follow-up
Participants are monitored for adherence to treatment and progression-free survival
Treatment Details
Interventions
- Nudge
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center at Penn Medicine
Lead Sponsor